Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineDaniel D. Von Hoff, Markus F. Renschler, Thomas J. Ervin et al.|New England Journal of Medicine|2013Cited by 6.6k
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Peng Sun et al.|The Lancet Oncology|2012Cited by 541
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Jeffrey R. Infante et al.|Cancer Discovery|2017Cited by 418